Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 3/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | TPH1 | P17752 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | CKS1B | P61024 | 1/20 | 0.32 |
| ▸ | SKP1 | P63208 | 1/20 | 0.32 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18931047 | 0.91 | PDK1 (0.38) | SMOHSD11B1MAP4K4TPH1MEN1 | |
| SCHEMBL21644386 | 0.83 | OPRK1 (0.35) | SMOHSD11B1MAP4K4MEN1KMT2A | |
| SCHEMBL22363580 | 0.83 | NR1H2 (0.39) | SMONR1H2NR1H3 | |
| SCHEMBL23838138 | 0.82 | HSD11B1 (0.36) | SMOHSD11B1MAP4K4MEN1KMT2A | |
| SCHEMBL20074072 | 0.81 | CYP11B2 (0.38) | SMOHSD11B1MAPK8NR1H2NR1H3 | |
| SCHEMBL20072195 | 0.81 | PTGER4 (0.44) | SMOHSD11B1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23838140 | 0.81 | NR1H2 (0.42) | SMOMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL20072210 | 0.81 | ALDH1A1 (0.39) | SMOHSD11B1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21644348 | 0.81 | HSD11B1 (0.33) | SMOHSD11B1MAP4K4MEN1KMT2A | |
| SCHEMBL18838746 | 0.81 | NR1H2 (0.39) | SMOMEN1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3383853-B1 | HOMOBISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR (LXR) BETA AGONISTS FOR TREATING E.G. ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-3383853-B1 | HOMOBISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR (LXR) BETA AGONISTS FOR TREATING E.G. ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2020-11-04 | — | — | EP | disclosed |
| US-10752587-B2 | Homobispiperidinyl derivatives as liver X receptor beta agonists, compositions and their use | MERCK SHARP & DOHME CORP. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10752587-B2 | Homobispiperidinyl derivatives as liver X receptor beta agonists, compositions and their use | MERCK SHARP & DOHME CORP. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20180354901-A1 | HOMOBISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2018-12-13 | — | — | US | disclosed |
| EP-3383853-A1 | HOMOBISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | Merck Sharp & Dohme Corp. (US) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017095758-A1 | HOMOBISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2017-06-08 | — | — | WO | disclosed |
| WO-2017095758-A1 | HOMOBISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752587-B2 | Homobispiperidinyl derivatives as liver X receptor beta agonists, compositions and their use | NR1H2, NR1H3, NR1H4 | SMO 3862/4885HSD11B1 63/4885MAP4K4 3849/4885 |
| US-20180354901-A1 | HOMOBISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS AND THEIR USE | NR1H2, NR1H3, NR1H4 | SMO 3862/4885HSD11B1 63/4885MAP4K4 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.